Discussion split from discussion of an NIH webinar where there was a presentation of a forthcoming Bergquist CSF proteomics study USA: NIH National Institutes of Health news Does anyone know if CSF proteomics has been used to study other illnesses?
There was this study: A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid James N Baraniuk et al. BMC Neurol. 2005. https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-5-22
Also Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome Steven E Schutzer et al. PLoS One. 2011. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0017287
Small world. I was recruited for this for the CFS cohort, and also considered for the PTLD part; I declined regardless: And I was in a subsequent one to this below with the Georgetown U folks.
Some recent papers in neurodegenerative diseases, esp AD — Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease (2023, Nature Medicine) Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease (2023, Science Translational Medicine) Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer’s disease biomarkers (2023, Cell Reports Medicine) CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels (2022, Nature Aging) Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s disease (2022, Cell Reports Medicine) Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease (2020, Science Advances)
I don't think I know the BPS sense of it, probably for the best. The Baraniuk study uses a very confusing and problematic definition of CFS. There was also a CSF metabolomics that I was excited about, from Fiehn Columbia, which was never published. I could've sworn it was in one of Cornell or Columbia's proposed studies for their NIH Center for Excellence grants.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and fibromyalgia are indistinguishable by their cerebrospinal fluid proteomes 2022, Schutzer et al There was this recent paper, also from the Bergquist team. Forum members were generally underwhelmed, mainly due to the lack of a healthy control comparison. It's good to see that the latest Bergquist study includes not only ME/CFS and Long Covid cohorts, but also a healthy control cohort. The post-treatment Lyme disease study was also from the Bergquist team. (sorry for late edits)
It's a reference to the frequent use of the word "promising" to describe BPS findings that are at best modest; but more realistically reflecting natural recovery, regression to mean, hopelessly confusion by uncontrolled expectation bias and generally incompetent methodology, and the muddled thinking exemplified by frequent correlation/causation confusion. Also CSF proteomics is going to really challenge editors now that we'll have more "ME/CFS CSF" studies. Hopefully the findings will help get us to a definitive disease name soon
Now that I can absolutely confirm. It's definitely made me double and triple check my comments over the years.
I assume someone's posted a link to Jonas's Twitter post - https://twitter.com/user/status/1695098547044053259
Moved post It was done several years ago, pooled csf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044169/ Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome Steven E. Schutzer,# 1 , * Thomas E. Angel,# 4 Tao Liu,# 4 Athena A. Schepmoes, 4 Therese R. Clauss, 4Joshua N. Adkins, 4 David G. Camp, II, 4 Bart K. Holland, 3 Jonas Bergquist, 5 Patricia K. Coyle, 6Richard D. Smith, 4 Brian A. Fallon, 7 and Benjamin H. Natelson 2 , 8